The Readout Loud

News & Politics Podcasts

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Episodes

401: Makary’s departure and Cassidy’s tenuous Senate seat

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

399: Hair-raising trial results, and Servier’s M&A wishlist

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

396: A new trick for old science, and biotech VCs' scrambled playbook

395: Biotech investors' plea to Trump, and a busy M&A week

394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy

393: A conversation with the 'godfather' of biotech

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

391: Breaching the IBD efficacy ceiling, and sham surgeries

390: FDA turmoil, election intrigue, AI, and more

389: Hims' Super Bowl fallout, and the FDA reverses course

388: The FDA's refusal to review Moderna's mRNA flu vaccine

387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

From Drug Story: Lipitor and Heart Disease

386: The high stakes for Huntington's patients

385: A measles outbreak and hospitals' financial troubles

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

383: JPM to bring more deals and happy CEOs